Meeting
2022 ASCO Annual Meeting
EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study.
Authors
Wolfgang Wick
Universitätsklinikum Heidelberg and German Cancer Research Center, Heidelberg, Germany
Wolfgang Wick , Ahmed Idbaih , Ghazaleh Tabatabai , María Vieito , Agostina Stradella , François Ghiringhelli , Michael C. Burger , Iris Mildenberger , Ulrich Herrlinger , Mirjam Renovanz , Mehdi Touat , Patrick Y. Wen , Antje Wick , Christophe Bonny , Jan Fagerberg , Cécile Gouttefangeas , Ana Maia , David A. Reardon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT04116658
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2034)
DOI
10.1200/JCO.2022.40.16_suppl.2034
Abstract #
2034
Poster Bd #
372
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.
First Author: Wolfgang Wick
Poster
2022 ASCO Annual Meeting
EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Preliminary results of the SPENCER study.
First Author: Eric Baudin
Poster
2021 ASCO Annual Meeting
Efficacy finding cohort of a cancer peptide vaccine, TAS0313, in treating recurrent glioblastoma.
First Author: Yoshiki Arakawa
Poster
2014 ASCO Annual Meeting
Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).
First Author: John Howard Sampson